Uncategorized

Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independence

Published

on

After the trailblazing approval of Sanofi’s Tzield for stage 3 type 1 diabetes, several companies, including SAB Biotherapeutics and Eledon Pharmaceuticals, are vying for a spot in the landscape with innovative approaches—and experts say there’s room for all of them.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version